Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Verubulin

Next Previous
X
Search
Drug Profile

Verubulin

Alternative Names: Azixa; EP-90745; MPC-6827; MX-128495; Veribulin

Latest Information Update: 27 Dec 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator EpiCept Corporation
  • Developer Immune Pharmaceuticals Inc; Myrexis
  • Class Antineoplastics; Quinazolines; Small molecules
  • Mechanism of Action Tubulin polymerisation inhibitors; Vascular disrupting agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioblastoma
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Brain metastases; Glioblastoma; Malignant melanoma
  • Phase 0 Neurodegenerative disorders
  • No development reported Solid tumours
  • Discontinued Colorectal cancer

Most Recent Events

  • 27 Dec 2022 Phase-0 development for Neurodegenerative disorders is ongoing in USA (IV) (NCT04575727)
  • 27 Dec 2022 Discontinued - Preclinical for Colorectal cancer (Combination therapy) in USA (IV)
  • 01 Oct 2020 Phase-0 for Neurodegenerative disorders (In volunteers) in USA (IV) (NCT04575727)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top